WAT Stock Recent News

Waters (WAT) reported earnings 30 days ago. What's next for the stock?

News Summary Up to six-fold increase in performance robustness with StepWave™ XR Ion Guide versus Xevo TQ Absolute.1 Uses up to 50% less power and gas, and occupies up to 50% less bench space than other products in its class.2 Takes the industry-leading sensitivity of Xevo TQ Absolute to new heights, including for PFAS detection and pharma quantitation applications. BALTIMORE and MILFORD, Mass.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

News Summary Enables measurements up to 2 days earlier for antibody titers for both clone selection and bioprocess monitoring.1 Provides up to 7x improvements in sensitivity with novel high efficiency particles.2 Delivers 2x more attribute information with simplified multi-attribute workflows.3 MILFORD, Mass. , May 28, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the launch of the BioResolve™ Protein A Affinity Columns with MaxPeak™ Premier Technology, providing precise titer measurements.

MILFORD, Mass. , May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies.

Norwegian Cruise Line showed a very slight earnings decline in Q1, reflecting a capacity and occupancy decline, offset by a good net yield gain. Macroeconomic headwinds create a more turbulent outlook for NCLH, as consumer weakness has caused more choppy bookings behavior for Q3. Notably, NCLH's performance and guidance both underperform Carnival Corporation and Royal Caribbean Cruises, making the company's commercial performance unclear.

MILFORD, Mass. , May 16, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.

U.S.-based Waters Corp , which makes medical equipment used in clinical testing, has seen a spurt in demand from drugmakers in India rushing to develop their versions of popular weight-loss drugs, a senior executive told Reuters.

WAT's first-quarter 2025 results reflect strong growth in the instruments and chemical segments, coupled with strong momentum in the industrial and pharma sectors.

Waters Corporation's stock remains a "Hold" due to high valuation multiples, despite a 35% increase in stock price and improved business performance. The company reported solid Q1 2025 results, with 3.9% revenue growth and 18% EPS growth, but valuation remains above historical averages. Management is optimistic about future growth, citing opportunities in the Indian market, GLP-1 testing, and pricing strategies, expecting high single-digit revenue growth.